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Community respiratory virus infections in the 
imunocompromised host 
S. Ghosh,” E. Whimbey and G. P Bodey 
*The University of Texas M.D. Anderson Cancer 
Center, Houston, Texas 
During the last 15 years community respiratory virus 
(CRV) infections have been recognized as a not in- 
frequent cause of serious illnesses in patients with 
acute leukemia and in bone marrow transplant (BMT) 
recipients. Most of the reported series include relatively 
small number of cases over a protracted period of time. 
During the last 3 years we became aware of the in- 
creasing number of these infections in our institution 
and hence, conducted a review to determine the 
incidence and outcome compared to our previous 
experience. Between July 2000 and March 2002, 321 
cases of CRV infections were diagnosed among adult 
patients with acute respiratory illnesses (ARI), the 
majority of whom were BMT recipients and patients 
with hematologic malignancies. There were 104 cases 
(32%) of respiratory syncytial viruses (RSV), 74 (23%) 
influenza A, 37 (12%) influenza B, 73 (23%) para- 
influenza and 33 cases (10%) of picornaviruses. The 
infection progressed to pneumonia in 113 cases (35%) 
of whom 33% had RSV, 32% influenza, 25% para- 
influenza and 11% picornaviruses. Overall pneumonia- 
associated mortality was 13% (RSV 19%, parainfluenza 
14%, influenza 8% and picornaviruses 8%). All the 
patients with pneumonia had radiographic evidence of 
pneumonia and virus was cultured from broncho- 
alveolar lavage fluids in 31 cases and in 84 cases diag- 
nosis was made only from nasopharyngeal wash/throat 
swab specimens. There was no standardized treatment 
utilized but patients who received early treatment with 
aerosolized ribavirin with IVIG and/or palivizumab for 
RSV and oseltamivir for influenza and parainfluenza 
viruses appeared to have reduced progression to 
pneumonia and reduced pneumonia-associated mor- 
tality. During the earlier period between 1992-1994, the 
frequency of progression of CRV infections to pneu- 
monia and the mortality rates were substantially higher 
( RSV 38% and 60%, influenza 53% and 46% and 
parainfluenza 44% and 37% respectively). In conclusion, 
early diagnosis and treatment is associated with better 
outcome in adults with acute leukemia and BMT 
recipients who develop ARI. 
Hepatitis C infection in hemodialysis patients 
A. M. Vedjakov, VA. Gavrilin, N. I. Razlivaeva, 
A. G. Tonevitsky 
Institute of Transplantology and Artificial Organs, 
Moscow, Russia 
Patients with chronic kidney failure receiving program- 
mable hemodialysis therapy suffer from immuno- 
deficiency. Chronic intoxication and some peculiarities 
in homeostasis of these patients may have a substantial 
influence on the course of viral infections, hepatitis C 
virus (HCV) infection in particular. 
Objectives: The study of the differences in the course of 
HCV infection in hemodialysis and immunocompetent 
patients. 
Methods: 28 hemodialysis patients and 30 immuno- 
competent patients, anti-HCV seropositive, were studied. 
In hemodialysis patients, two blood samples were studied 
in parallel, one taken before, and another one after 
hemodialysis. HCV RNA in plasma was detected by 
nested-PCR (RT-PCR) method. Primers, comple- 
mentary to 5’ non-translated region, were used. Vaccine 
strain of measles virus was used as a non-competent 
internal control in PCR analysis. Semi-quantitative 
assessment of PCR results was carried out by limiting 
dilutions of samples. HCV-specific IgM, IgG antibodies 
and antibodies against viral proteins core, NS3, NS4, and 
NS5 were detected by ELISA. 
Results: Among 30 immunocompetent anti-HCV 
seropositive patients, HCV RNA was detected in 29 
(90%) and anti-HCV IgM in 21 (70%). Among 28 
hemodialysis anti-HCV seropositive patients, HCV 
RNA was detected in 19 (68%), and anti-HCV IgM in 
11 (39%). The results of PCR analysis of blood samples 
before and after hemodialysis were identical. The levels 
of viral load in the group of hemodialysis patients 
with HCV viremia were also lower compared with 
control group. Comparative analysis of humoral immune 
response to HCV viral proteins core, NS3, NS4, and NS5 
did not show substantial differences between the control 
group and the group of hemodialysis patients. Among 
anti-HCV seropositive hemodialysis patients, 63% of 
those without HCV viremia exhibited HLA phenotype 
DR5+, while only 33% of those with HCV viremia 
exhibited the same phenotype. 
Conclusion: A peculiar course of chronic hepatitis C 
virus (HCV) infection in hemodialysis patients had been 
revealed. In such anti-HCV seropositive patients, a 
viremia appeared significantly rare (in 68% cases) in 
comparison with a usual population of seropositive anti- 
HCV patients (in 90% cases). 
Oncogenic type of human papilioma virus (HPV) 
revealed by PCR in the oral mucosa of the kidney 
allograft recipients 
P Fiedor, A. Wojtowicz, t K. Ciechowicz,t M. Malejcz.yk,2 
D. Szubiska,’ L. Chomicz,3 K. Szymaska” 
*Department of General and Transplantation Surgery, 
‘Department of Dental Surgery. 2Department of 
Sexually Transmitted Diseases. 3Department of General 
Biology and Parasitology. 4Department of Pathological 
Anatomy, Medical University of Warsaw, Poland 
The aim of the study was to assess changes in the 
oral cavity of kidney allograft recipients under chronic 
immunosuppression (Cyclosporin A, Azathioprine and 
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Encorton) with typing HPV 6,16 which were previously 
detected in anogenital region of the patients. 
One hundred recipients (20-65 aged) 0.5-18 years 
after allotransplantation were assessed clinically and 
histologically including biopsy of oral mucous and PCR 
techniques for HPV identification. Primers specific for 
E4 (HPV 6) and E6 (HPV 16) ORF were used for the 
amplification of HPV DNA present in samples. 
Epithelial verrucas differentiated in size, morphology 
and placement were found clinically in 10% patients. 
Thick, acantotic changed epithelium with numerous 
coilocytes and clear hiperproliferation was revealed in 
samples taken 
from all patients with the viral infection.Type 16 HPV 
were detected in 24% (24/100) of the recipients, type 6 
HPV occurred in 5% (5000) while both 16 HPV and 6 
HPV were revealed in 3 patients only. 
Our data indicate that the recipients with decreased 
immune response, the HPV infection and the chronic 
immunosuppression are at a major risk for the develop- 
ment of the oral neoplasm proliferations. The long term 
follow-up for detection of the oncogenic virus type as 
well as monitoring of the level of the immunosup- 
pression should be undertaken for protection against the 
development of the oral cancer in the kidney recipients. 
Monitoring of human cytomegalovirus infection 
by antigenemia assay in seropositive renal transplant 
recipients 
Murat Tuncer, Dilek Colak, Alihan Gurkan, 
Asuman Yavuz, Dilara Ogunc, Taner Colak, 
Okan Erdogan, Giizde Ongut, Berna Dalmq 
Alper Demirbas, Meral Gultekin, Fevzi Ersoy, 
Mustafa Akaydm, Gulsen Yakupoglu 
Akdeniz University Transplantation Center, 
Antalya, Turkey 
The aim of this study was to assess the data related to 
human cytomegalovirus (HCMV) of renal transplant 
recipients in our transplantation center. Between April 
2000 and March 2002,109 consecutive renal transplants 
(53 cadaveric, 56 living-related) were performed in our 
center. All the donors and recipients were HCMV 
seropositive (D +/R+). Living-related recipients received 
prednisolonelmycophenolate mofetil cyclosporine or 
tacrolimus as an immunosuppressive regimen. Cadaveric 
recipients received the same triple therapy plus poly- 
clonal antibody for 7 to 14 days as induction. Polyclonal 
antibody therapy was also given in acute vascular or 
clinically severe rejection episodes. In all patients, 
acyclovir or valaciclovir was given as a prophylactic 
treatment for six months. Evidence of HCMV infection 
was monitored by HCMV antigenemia assay weekly 
for three months, biweekly for 3-6 months and then 
monthly up to one year after transplantation. HCMV 
antigenemia was positive (median: 6.5/2X lo5 PBL, 
range: 1-924/2x lo5 PBL) in 50 of 109 (45%) recipients 
(cadaveric: 41%, living-related: 16%). The median time 
for first positive antigenemia was 54 (3-145) days. 
Seventeen of the 31 antigenemia positive recipients had 
high level antigenemia (250/2x 10” PBL) and six of 
them developed HCMV disease (p<O.OOl). Twenty-six 
of 31 patients received ganciclovir for 20.4k2.7 days. 
HCMV infection and disease rates were higher in 
cadaveric recipients (p<O.OOl, p=O.O8, respectively). 
The risks of leucopenia and increment in transaminase 
levels were higher if first antigenemia level was high 
(p=O.O34, p=O.O14, respectively). HCMV infection and 
disease have been seen more frequently in thymo- 
globulin receiving patients than in ATG group (Thymo- 
globulin:5/6, ATG:l/B). Acute rejection rate was higher 
in HCMV antigenemia positive recipients than in 
negative recipients (28% vs. 13%; p=O.O61). Four of six 
recipients (12%) who have the disease died due to 
HCMV in the follow-up period. Our results suggested 
that polyclonal antibody treatment increases the rate of 
HCMV infection. We believe that monitoring of HCMV 
infection by antigenemia assay is a reasonable procedure 
and if antigen level is higher than r50/2x105 PBL, 
ganciclovir must be initiated, especially in recipients 
with leucopenia and high transaminase levels. 
A report of JC virus in a 33-year-old patient with 
systemic lupus erythematosus (SLE) 
H. L. Durham, J. B. Garcia-Diaz, M. G. Ochsner 
Clinic Foundation, * New Orleans, LA, USA 
During the first two decades after 1958 when Anstrom 
et al first identified promyelocytic leukemia (PML), there 
were fewer than 100 pathologically confirmed cases of 
the disease. The diagnosis was most likely to be found in 
association with hematologic malignancies. With the 
onset of the HIV/AIDS epidemic the number of cases 
of PML escalated and the diagnosis became a relative 
frequent and important consideration in patients with 
advanced immunosuppression. In the summer of 2001 a 
33-year-old female patient with a subacute presentation 
of motor deficits was transferred to our hospital. 
The patient had a 6-month history of progressive 
motor deficits with periodic attenuation but without 
return to base line function. At admission she was bed 
bound without movement of her left extremities and of 
her right lower extremity. A month before admission she 
had been in rehabilitation ambulating and performing 
her own activities of daily living. She had a cushingoid 
appearance. Over the prior 6 months serial CT and MRI 
brain scans had shown lesions reported to represent 
cerebrovascular accidents. She had a history of SLE 
diagnosed when she was 6 years old. In 1979 the diag- 
nosis was confirmed by renal and skin biopsies. Through- 
out childhood and adolescence she had received 
symptomatic relief with prednisone therapy. In the late 
winter of 2000 she had exacerbations of symptoms 
attributed to SLE and been treated with prednisone in 
